Lymphoplasmacytic lymphoma CT scan

Lymphoplasmacytic lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lymphoplasmacytic Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lymphoplasmacytic lymphoma CT scan On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma CT scan All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lymphoplasmacytic lymphoma CT scan
CDC on Lymphoplasmacytic lymphoma CT scan
Lymphoplasmacytic lymphoma CT scan in the news
Blogs on Lymphoplasmacytic lymphoma CT scan
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Lymphoplasmacytic lymphoma CT scan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2]

Overview

In lymphoplasmacytic lymphoma, CT scan imaging of chest, abdomen, and pelvis may show evidences of lymphadenopathy and hepatomegaly. CT of the lungs or abdomen can also be diagnostic for infection, which is particularly relevant to immunocompromised patients.

CT scan

• CT scan imaging with IV contrast of chest, abdomen, and pelvis can be done to measure the tumor load.
• Lymphoplasmacytic lymphoma shows evidence of lymphadenopathy, and hepatosplenomegaly.
• CT of the lungs or abdomen can also be diagnostic for infection, which is particularly relevant to immunocompromised patients.

Abdominal computed tomography (CT) showing significant hemoperitoneum, with extravasation of contrast into the right flank/paracolic gutter. Hepatomegaly and splenomegaly are clearly seen. [https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-7&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=21 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia. ]

Transaxial slices representative of the isodose distribution of the 3D-CRT treatment plan delivered for the whole spleen. A, In the first stage, isodose curves were produced by 3 oblique isocentric photon fields of beam quality 10-MV; B, In the second stage, isodose curves were produced by 5 oblique isocentric photon fields of beam quality 10-MV. Source: Wei Z. et al, Department of Radiotherapy, Cancer Centre, Qilu Hospital, Shandong University, 107 Wenhuaxi Street, Jinan, Shandong 250012, China.

Response to mTOR-inhibitor treatment in Waldenstrom's macroglobulinemia and lung toxicity. Baseline contrast-enhanced coronal CT images in a 59-year-old woman show retroperitoneal lymphadenopathy (black arrows) and mild splenomegaly (A). Five months after the start of treatment, coronal contrast-enhanced CT shows decreased adenopathy and splenomegaly (B). At baseline, clear lung bases were present (C). On a five-month follow-up CT (D), new ground-glass and reticular opacities developed in lung bases (white arrows), in keeping with mTOR-associated pneumonitis. The patient was asymptomatic. mTOR = mammalian target of rapamycin.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC5240491_kjr-18-28-g007&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=36 Source: Krajewski KM. et al, Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Radiology, Brigham and Women's Hospital, Boston, MA 02115, USA ]

(A) Contrast-enhanced axial and coronal T1-weighted images show a well-enhanced mass along the left tentorium and cavernous sinus (arrows). This mass also extends into the contralateral tentorium and falx (arrowheads). (B) A marked decrease in the size of the mass in the tentorium and falx after radiation therapy and fludarabine treatment.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2694623_jkms-22-1079-g001&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=28 Source: Kim HD. et al, Department of Internal Medicine, Yeoungnam University College of Medicine, Daegu, Korea. ]

Sequential computed tomography scan images at the same level. A, At the diagnosis of the disease (19/06/2008); B, Relapsed after chlorambucil and thalidomide (25/06/2009); C, Before the first stage of 3D-CRT (12/12/2009); D, Before the second stage of 3D-CRT (22/06/2010); E, At one month after the second stage of 3D-CRT (17/08/2010); F, At one year after the second stage of 3D-CRT (06/07/2011). [https://openi.nlm.nih.gov/detailedresult.php?img=PMC3428667_1748-717X-7-58-1&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=55 Source: Wei Z. et al, Department of Radiotherapy, Cancer Centre, Qilu Hospital, Shandong University, 107 Wenhuaxi Street, Jinan, Shandong 250012, China. ]